Overcoming T cell exhaustion in infection and cancer.

[1]  L. Fu,et al.  Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review. , 2015, Critical reviews in oncology/hematology.

[2]  H. Lähdesmäki,et al.  The transcription factor NFAT promotes exhaustion of activated CD8⁺ T cells. , 2015, Immunity.

[3]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[4]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[5]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[6]  Bosco K. Ho,et al.  Granzyme B promotes cytotoxic lymphocyte transmigration via basement membrane remodeling. , 2014, Immunity.

[7]  J. Hackney,et al.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.

[8]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[9]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[10]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[11]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[12]  S. Kaech,et al.  The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. , 2014, Immunity.

[13]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[14]  J. Schenkel,et al.  Resident memory CD8 T cells trigger protective innate and adaptive immune responses , 2014, Science.

[15]  Hao Shen,et al.  Epigenetic Manipulation Restores Functions of Defective CD8+ T Cells From Chronic Viral Infection. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  O. Lund,et al.  T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection , 2014, PLoS pathogens.

[17]  Jonathan D. Powell,et al.  Integrating canonical and metabolic signalling programmes in the regulation of T cell responses , 2014, Nature Reviews Immunology.

[18]  Sven Malchow,et al.  Shaping the repertoire of tumor‐infiltrating effector and regulatory T cells , 2014, Immunological reviews.

[19]  Loise M. Francisco,et al.  RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance , 2014, The Journal of experimental medicine.

[20]  D. Douek,et al.  PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. , 2014, The Journal of clinical investigation.

[21]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Ahmed,et al.  Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection , 2014, The Journal of experimental medicine.

[23]  Burton E. Barnett,et al.  Molecular and transcriptional basis of CD4⁺ T cell dysfunction during chronic infection. , 2014, Immunity.

[24]  Ronald N Germain,et al.  Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. , 2014, Immunity.

[25]  P. Greenberg,et al.  Tolerance and exhaustion: defining mechanisms of T cell dysfunction. , 2014, Trends in immunology.

[26]  J. Wolchok,et al.  Immune modulation in cancer with antibodies. , 2014, Annual review of medicine.

[27]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[28]  M. Jenkins,et al.  PD-1, but Not PD-L1, Expressed by Islet-Reactive CD4+ T Cells Suppresses Infiltration of the Pancreas During Type 1 Diabetes , 2013, Diabetes.

[29]  Todd M. Allen,et al.  Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells , 2013, The Journal of Immunology.

[30]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[31]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[32]  J. Wolchok,et al.  At the Bedside: CTLA‐4‐ and PD‐1‐blocking antibodies in cancer immunotherapy , 2013, Journal of leukocyte biology.

[33]  W. Gillanders,et al.  The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer , 2013, Breast Cancer Research and Treatment.

[34]  A. Legat,et al.  T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion , 2013, Nature Immunology.

[35]  R. Schreiber,et al.  Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling , 2013, Science.

[36]  B. Aronow,et al.  Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection , 2013, Science.

[37]  Michael Loran Dustin,et al.  PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis , 2013, The Journal of experimental medicine.

[38]  J. Gribben,et al.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. , 2013, Blood.

[39]  T. Zenz.  Exhausting T cells in CLL. , 2013, Blood.

[40]  E. Wherry,et al.  Technical Advance: Fluorescent reporter reveals insights into eomesodermin biology in cytotoxic lymphocytes , 2013, Journal of leukocyte biology.

[41]  E John Wherry,et al.  Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. , 2012, Immunity.

[42]  Burton E. Barnett,et al.  Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection , 2012, Science.

[43]  J. Taube,et al.  Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody , 2012, Clinical Cancer Research.

[44]  S. Kaech,et al.  Transcriptional control of effector and memory CD8+ T cell differentiation , 2012, Nature Reviews Immunology.

[45]  P. Hwu,et al.  PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. , 2012, Cancer research.

[46]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[47]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[48]  V. Boussiotis,et al.  Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation , 2012, Science Signaling.

[49]  Takashi Saito,et al.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 , 2012, The Journal of experimental medicine.

[50]  Jill M. Angelosanto,et al.  Progressive Loss of Memory T Cell Potential and Commitment to Exhaustion during Chronic Viral Infection , 2012, Journal of Virology.

[51]  J. Allison,et al.  Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin , 2012, The Journal of experimental medicine.

[52]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[53]  J. Delrow,et al.  Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State , 2012, Science.

[54]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[55]  J. Wolchok,et al.  Novel cancer immunotherapy agents with survival benefit: recent successes and next steps , 2011, Nature Reviews Cancer.

[56]  David A. Orlando,et al.  Master Transcription Factors Determine Cell-Type-Specific Responses to TGF-β Signaling , 2011, Cell.

[57]  L. Zon,et al.  Lineage Regulators Direct BMP and Wnt Pathways to Cell-Specific Programs during Differentiation and Regeneration , 2011, Cell.

[58]  R. Ahmed,et al.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. , 2011, Immunity.

[59]  E. Wherry.  T cell exhaustion , 2011, Nature Immunology.

[60]  Pedro Romero,et al.  Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. , 2011, The Journal of clinical investigation.

[61]  A. Intlekofer,et al.  T-bet represses expression of PD-1 and sustains virus-specific CD8 T cell responses during chronic infection , 2011, Nature Immunology.

[62]  D. McGavern,et al.  Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells , 2011, The Journal of experimental medicine.

[63]  Michael J. Zilliox,et al.  Phenotype, Function, and Gene Expression Profiles of Programmed Death-1hi CD8 T Cells in Healthy Human Adults , 2011, The Journal of Immunology.

[64]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[65]  Kristen E. Pauken,et al.  The role of the PD‐1 pathway in autoimmunity and peripheral tolerance , 2011, Annals of the New York Academy of Sciences.

[66]  Todd M. Allen,et al.  Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. , 2010, The Journal of clinical investigation.

[67]  E. Wherry,et al.  Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche , 2010, The Journal of Immunology.

[68]  Björn Nilsson,et al.  Integrative genomic analysis of HIV-specific CD8+ T cells reveals that PD-1 inhibits T cell function by upregulating BATF , 2010, Nature Medicine.

[69]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[70]  Yan Zhang,et al.  Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer , 2010, Cellular and Molecular Immunology.

[71]  J. Harty,et al.  Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. , 2010, Immunity.

[72]  G. Freeman,et al.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection , 2010, Proceedings of the National Academy of Sciences.

[73]  Scott N. Mueller,et al.  PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. , 2010, The Journal of clinical investigation.

[74]  J. Taube,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Lloyd J. Old,et al.  Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer , 2010, Proceedings of the National Academy of Sciences.

[76]  J. Mulé,et al.  Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against Melanoma , 2010, The Journal of Immunology.

[77]  R. Ahmed,et al.  Features of responding T cells in cancer and chronic infection. , 2010, Current opinion in immunology.

[78]  W. Isaacs,et al.  Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+ , 2009, The Prostate.

[79]  J. Bluestone,et al.  Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal , 2009, Nature Immunology.

[80]  E. Wherry,et al.  A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. , 2009, Immunity.

[81]  S. Rosenberg,et al.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.

[82]  K. Sauer,et al.  IL-21 Is Required to Control Chronic Viral Infection , 2009, Science.

[83]  A. Zajac,et al.  A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection , 2009, Science.

[84]  J. Weber,et al.  IL-21R on T Cells Is Critical for Sustained Functionality and Control of Chronic Viral Infection , 2009, Science.

[85]  J. Riley.  PD‐1 signaling in primary T cells , 2009, Immunological reviews.

[86]  J. Kirkwood,et al.  PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients1 , 2009, The Journal of Immunology.

[87]  E. Wherry,et al.  Impact of Epitope Escape on PD-1 Expression and CD8 T-Cell Exhaustion during Chronic Infection , 2009, Journal of Virology.

[88]  G. Freeman,et al.  Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade , 2009, PLoS pathogens.

[89]  J. Sprent,et al.  Homeostasis of naive and memory T cells. , 2008, Immunity.

[90]  R. Ahmed,et al.  NFATc1 Regulates PD-1 Expression upon T Cell Activation1 , 2008, The Journal of Immunology.

[91]  G. Freeman,et al.  Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade , 2008, Proceedings of the National Academy of Sciences.

[92]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[93]  J. Schwaller,et al.  Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. , 2007, Blood.

[94]  E. Wherry,et al.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.

[95]  E. Wherry,et al.  Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells , 2007, The Journal of experimental medicine.

[96]  E. Wherry,et al.  Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection , 2007, The Journal of experimental medicine.

[97]  L. Teyton,et al.  Interleukin-10 determines viral clearance or persistence in vivo , 2006, Nature Medicine.

[98]  E. Usherwood,et al.  Gammaherpesvirus Persistence Alters Key CD8 T-Cell Memory Characteristics and Enhances Antiviral Protection , 2006, Journal of Virology.

[99]  R. Ahmed,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[100]  E. Wherry,et al.  Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin , 2005, Nature Immunology.

[101]  L. Teyton,et al.  Intrinsic Functional Dysregulation of CD4 T Cells Occurs Rapidly following Persistent Viral Infection , 2005, Journal of Virology.

[102]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[103]  T. Honjo,et al.  PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. , 2004, International immunology.

[104]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[105]  E. Wherry,et al.  Antigen-independent memory CD8 T cells do not develop during chronic viral infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[106]  K. Sheppard,et al.  PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ , 2004 .

[107]  C. June,et al.  SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 , 2004, The Journal of Immunology.

[108]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[109]  Bette Korber,et al.  Epitope Escape Mutation and Decay of Human Immunodeficiency Virus Type 1-Specific CTL Responses 1 , 2003, The Journal of Immunology.

[110]  J. Cheville,et al.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.

[111]  D. Rouleau,et al.  Longitudinal Assessment of Changes in HIV-Specific Effector Activity in HIV-Infected Patients Starting Highly Active Antiretroviral Therapy in Primary Infection 1 , 2003, The Journal of Immunology.

[112]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[113]  E. Wherry,et al.  Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment , 2003, Journal of Virology.

[114]  R. Schwartz.  T cell anergy. , 2003, Annual review of immunology.

[115]  A. Zajac,et al.  Ablation of CD8 and CD4 T Cell Responses by High Viral Loads1 , 2003, The Journal of Immunology.

[116]  H. Günthard,et al.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[117]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[118]  A. Frey,et al.  CD8+ Tumor-Infiltrating T Cells Are Deficient in Perforin-Mediated Cytolytic Activity Due to Defective Microtubule-Organizing Center Mobilization and Lytic Granule Exocytosis , 2001, The Journal of Immunology.

[119]  B. Walker,et al.  Sustained Dysfunction of Antiviral CD8+ T Lymphocytes after Infection with Hepatitis C Virus , 2001, Journal of Virology.

[120]  Stefan Kostense,et al.  High viral burden in the presence of major HIV‐specific CD8+ T cell expansions: evidence for impaired CTL effector function , 2001, European journal of immunology.

[121]  M. Mulligan,et al.  A Significant Number of Human Immunodeficiency Virus Epitope-Specific Cytotoxic T Lymphocytes Detected by Tetramer Binding Do Not Produce Gamma Interferon , 2000, Journal of Virology.

[122]  J. Lieberman,et al.  Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. , 2000, Blood.

[123]  B. Walker,et al.  Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus , 2000, The Journal of experimental medicine.

[124]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[125]  L. Weinberger,et al.  Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.

[126]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[127]  J. Altman,et al.  Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function , 1998, The Journal of experimental medicine.

[128]  R. Zinkernagel,et al.  Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection. , 1998, Immunity.

[129]  R. Zinkernagel,et al.  Induction and Exhaustion of Lymphocytic Choriomeningitis Virus–specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class I–Peptide Complexes , 1998, The Journal of experimental medicine.

[130]  R. Ahmed,et al.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection , 1994, Journal of virology.

[131]  Yu Yao,et al.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. , 2015, Trends in molecular medicine.

[132]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[133]  K. Sheppard,et al.  PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. , 2004, FEBS letters.

[134]  A. King,et al.  Escaping High Viral Load Exhaustion: CD8 Cells with Altered Tetramer Binding in Chronic Hepatitis B Virus Infection , 2002 .

[135]  L. Bradley,et al.  T cell memory. , 1998, Annual review of immunology.